NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 17 04:00PM ET
1.77
Dollar change
+0.05
Percentage change
2.91
%
IndexRUT P/E- EPS (ttm)-1.03 Insider Own18.71% Shs Outstand141.98M Perf Week-0.56%
Market Cap450.17M Forward P/E- EPS next Y-0.19 Insider Trans0.35% Shs Float116.77M Perf Month-27.16%
Income-144.85M PEG- EPS next Q-0.07 Inst Own85.98% Short Float11.25% Perf Quarter-61.27%
Sales259.19M P/S1.74 EPS this Y-154.72% Inst Trans-1.96% Short Ratio3.90 Perf Half Y-78.65%
Book/sh2.29 P/B0.77 EPS next Y24.61% ROA-11.61% Short Interest13.13M Perf Year-78.26%
Cash/sh1.27 P/C1.40 EPS next 5Y5.51% ROE-39.04% 52W Range1.68 - 11.56 Perf YTD-67.52%
Dividend Est.- P/FCF- EPS past 5Y-64.27% ROI-21.04% 52W High-84.68% Beta0.29
Dividend TTM- Quick Ratio6.65 Sales past 5Y42.54% Gross Margin33.60% 52W Low5.36% ATR (14)0.20
Dividend Ex-Date- Current Ratio7.53 EPS Y/Y TTM-14.44% Oper. Margin-26.26% RSI (14)29.16 Volatility6.81% 8.78%
Employees570 Debt/Eq1.16 Sales Y/Y TTM-10.30% Profit Margin-55.89% Recom2.20 Target Price5.23
Option/ShortYes / Yes LT Debt/Eq1.12 EPS Q/Q77.00% Payout- Rel Volume0.67 Prev Close1.72
Sales Surprise-1.43% EPS Surprise-51.13% Sales Q/Q-23.92% EarningsMar 18 AMC Avg Volume3.36M Price1.77
SMA20-13.48% SMA50-37.59% SMA200-70.98% Trades Volume2,242,188 Change2.91%
Date Action Analyst Rating Change Price Target Change
Feb-26-25Downgrade Robert W. Baird Outperform → Neutral $9 → $3
Dec-19-24Initiated Guggenheim Neutral
Dec-05-24Downgrade Goldman Neutral → Sell $4.25
Nov-14-24Initiated Wolfe Research Peer Perform
Nov-08-24Downgrade William Blair Outperform → Mkt Perform
Aug-28-24Initiated Wells Fargo Overweight $10
Aug-13-24Downgrade Morgan Stanley Overweight → Equal-Weight $11 → $10
Apr-10-24Initiated Craig Hallum Buy $15
Dec-12-23Upgrade BofA Securities Neutral → Buy $10 → $8
Aug-08-23Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Apr-16-25 06:10PM
Apr-15-25 09:35AM
Apr-14-25 01:13PM
Apr-11-25 01:31PM
Apr-10-25 11:34AM
04:37AM Loading…
04:37AM
Apr-04-25 02:34PM
Apr-03-25 06:21PM
Apr-01-25 01:23PM
Mar-26-25 11:10AM
Mar-25-25 12:49PM
Mar-24-25 02:33PM
Mar-22-25 10:30AM
Mar-21-25 08:00PM
01:43PM
09:00PM Loading…
Mar-20-25 09:00PM
Mar-18-25 04:05PM
05:45AM
Mar-17-25 02:22AM
Mar-16-25 09:32AM
Mar-08-25 10:15AM
Feb-28-25 09:31AM
Feb-27-25 06:37PM
Feb-25-25 06:00AM
Feb-24-25 08:00AM
Feb-04-25 04:01PM
Feb-03-25 06:00AM
Jan-28-25 04:01PM
Jan-20-25 11:02PM
Jan-08-25 04:10PM
07:15AM Loading…
Dec-20-24 07:15AM
Dec-05-24 04:05PM
Nov-12-24 08:05AM
Nov-09-24 06:51AM
Nov-08-24 02:20PM
03:15AM
02:34AM
Nov-07-24 04:01PM
04:01PM
Oct-15-24 04:05PM
Oct-09-24 08:03AM
Sep-24-24 08:12AM
Aug-28-24 07:49AM
Aug-12-24 08:05AM
Aug-08-24 12:45AM
Aug-07-24 04:05PM
Jul-29-24 04:05PM
Jul-10-24 08:00AM
Jul-02-24 04:00PM
Jun-20-24 09:15AM
Jun-17-24 09:54AM
Jun-12-24 02:38AM
May-17-24 11:52AM
May-13-24 08:00AM
May-09-24 04:18PM
04:05PM
10:53AM
10:11AM
04:02AM
03:15AM
May-08-24 08:57PM
04:05PM
Apr-30-24 07:31AM
Apr-18-24 07:36AM
Apr-10-24 04:05PM
Mar-28-24 04:00PM
Mar-19-24 07:48AM
Mar-12-24 04:15PM
Feb-23-24 12:15PM
10:10AM
Feb-22-24 08:30PM
04:43PM
04:05PM
Feb-21-24 08:00AM
Feb-13-24 08:30AM
Feb-11-24 05:00PM
Feb-07-24 06:46AM
Jan-29-24 08:00AM
Dec-18-23 05:27AM
Nov-24-23 08:39AM
Nov-09-23 08:15AM
Nov-08-23 04:02PM
12:00AM
Nov-07-23 04:49PM
04:05PM
Nov-02-23 06:47AM
Oct-20-23 12:08PM
Oct-17-23 08:15AM
Sep-29-23 12:43PM
08:15AM
Sep-25-23 08:49AM
Sep-19-23 09:31AM
Sep-05-23 04:15PM
Aug-23-23 08:15AM
Aug-22-23 08:14AM
Aug-09-23 04:15PM
06:03AM
Aug-08-23 06:20AM
01:30AM
Aug-07-23 04:05PM
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers' research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORESHACK KURTGeneral CounselJan 31 '25Sale5.0325,000125,750167,618Jan 31 06:20 PM
ORESHACK KURTOfficerJan 31 '25Proposed Sale5.0325,000125,750Jan 31 09:42 AM
DeFord John ADirectorNov 12 '24Buy5.7517,500100,62570,046Nov 14 04:32 PM
HULL CARLSee RemarksNov 11 '24Buy5.64175,000987,000175,000Nov 12 04:59 PM
GTCR INVESTMENT XI LLCDirectorMay 28 '24Sale9.819,940,97497,570,66020,150,005May 30 05:39 PM